Zevorcabtagene autoleucel
As of the edition of 20 October 2026, Zevorcabtagene autoleucel is a gene: in active development; acts on AXL, FLT3 and KDR and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Gene
- Registered trials
- 2, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 2 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CARsgen Therapeutics | Lead sponsor of trials | 2024 to now |